101
Views
4
CrossRef citations to date
0
Altmetric
Letter to the Editor

Intravitreal Bevacizumab for Choroidal Neovascular Membrane at the Edge of a Healed Choroidal Tuberculoma

, MD ORCID Icon, , MD & , MS
Pages 239-241 | Received 05 Apr 2016, Accepted 22 Jun 2016, Published online: 19 Aug 2016
 

ABSTRACT

The authors present a 36-year-old female with pulmonary tuberculosis who developed a choroidal tuberculoma in the left eye. The choroidal tuberculoma successfully resolved with visual gain following oral anti-tubercular and oral steroid therapy leaving behind a chorioretinal scar. One year after the completion of anti-tubercular treatment, she developed visual loss due to the development of a secondary choroidal neovascular membrane at the fovea. This was treated successfully with one intravitreal injection of bevacizumab in the left eye. The fovea remained free of fluid until the last follow-up 10 months after the intravitreal injection. Intravitreal bevacizumab may be an effective modality for treating secondary choroidal neovascular membranes that may form at the edge of a healed choroidal tuberculoma.

ACKNOWLEDGMENTS

We are grateful to Trina Sengupta Tripathy for her support and assistance in drafting the manuscript.

DECLARATION OF INTEREST

The authors report on conflicts of interest. The authors alone are responsible for the content and writing of the manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.